CC
SRPT icon

Corton Capital’s Sarepta Therapeutics SRPT Stock Holding History

Corton Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$232K Buy
12,020
+1,832
+18% +$32.7K 0.57% 69
2025
Q2 		$174K Buy
+10,188
New +$435K 0.2% 261
2024
Q4 		– Sell
-2,102
Closed -$263K – 624
2024
Q3 		$263K Buy
+2,102
New +$291K 0.13% 244

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Corton Capital's SRPT Position: Q3 2025 in Review

Corton Capital increased its Sarepta Therapeutics (SRPT) stake by 18% in Q3 2025, buying an estimated $32.7K and bringing the position to 12,020 shares worth $232K. The position accounts for 0.57% of the portfolio, ranked #69.

Corton Capital first reported a position in SRPT in Q3 2024 and has held it in 3 quarters since. The position peaked at $263K in Q3 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Corton Capital held 12,020 shares of Sarepta Therapeutics worth $232K as of Q3 2025.
  • Corton Capital bought 1,832 Sarepta Therapeutics shares in Q3 2025, an estimated $32.7K.
  • Sarepta Therapeutics made up 0.57% of Corton Capital's portfolio in Q3 2025, its #69 holding.
  • Corton Capital first reported a position in Sarepta Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • Corton Capital's Sarepta Therapeutics position peaked at $263K in Q3 2024.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Corton Capital's 13F filing for Q3 2025, filed 14 Nov 2025.